The Experts below are selected from a list of 16017 Experts worldwide ranked by ideXlab platform
Yu. G. Kaminsky - One of the best experts on this subject based on the ideXlab platform.
-
Impacts of Lisinopril and Lisinopril plus simvastatin on erythrocyte and plasma arginase, nitrite, and nitrate in hypertensive patients.
Journal of clinical pharmacology, 2011Co-Authors: Elena Kosenko, Lyudmila A. Tikhonova, Alexander Suslikov, Yu. G. KaminskyAbstract:Angiotensin-converting enzyme inhibitors are effective at reducing blood pressure, whereas statins decrease plasma cholesterol, impeding atherosclerosis. The authors hypothesize that these medications may improve blood pressure by modifying the arginase-nitric oxide synthase system of erythrocytes. In this study, the effects of Lisinopril alone versus Lisinopril + simvastatin on erythrocyte and plasma arginase enzyme and nitric oxide metabolites are compared. Patients with atherosclerosis and hypertension are randomly assigned to receive Lisinopril 10 to 20 mg/d or Lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d for 24 weeks. Higher arginase activity is observed in erythrocytes from 100% of patients and mainly recovered after 12 and 24 weeks of treatment with Lisinopril or Lisinopril + simvastatin. Plasma arginase activity is 3 orders of magnitude lower than erythrocyte arginase activity in all participants, suggesting a lack of its clinical significance. Both treatments cause the increase in plasma $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ , $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ , and $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ + $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ in 100% of patients. Erythrocyte $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ + $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ concentration is greatly decreased in hypertensive patients but recovers after monotherapy and combined therapy. The results show for the first time that Lisinopril monotherapy and combined Lisinopril + simvastatin therapy exhibit pronounced and equipotential normalizing effects on erythrocyte arginase and nitric oxide synthase activities.
-
Antioxidant enzymes in erythrocytes from hypertension patients receiving Lisinopril monotherapy or combined Lisinopril plus simvastatin therapy
Biomeditsinskaia khimiia, 2011Co-Authors: Elena Kosenko, A. V. Suslikov, N. I. Venediktova, Yu. G. KaminskyAbstract:Statins and angiotensin-converting enzyme (ACE) inhibitors have beneficial impact on the serum cholesterol and blood pressure. It is supposed that statins and ACE inhibitors may modify the antioxidative status of erythrocytes. The study objective was to compare the effects of two treatments, Lisinopril alone vs Lisinopril plus simvastatin, on erythrocyte antioxidant enzyme activities. The study involved 32 patients with arterial hypertension, the initial serum total cholesterol, LDL-cholesterol and triglycerides within the normal range. Patients of two groups, each of 16 subjects, were treated with Lisinopril (10 mg/day) or with Lisinopril (10 mg/day) plus simvastatin (20 mg/day). Before and after 3 and 6 months of follow-up therapy, activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GLR) in purified erythrocytes were determined. In all patients, significantly higher catalase activity (by 79.3-106.5%, p < 0.0001) and significantly lower GPx activity (by 20.7-30.6%, p < 0.001) were observed after therapy as compared to the baselines. Just the same results were obtained in both groups (Lisinopril and Lisinopril + simvastatin), after both periods (3 and 6 month) of treatments. SOD activity was increased only in the Lisinopril group and only after 6 months (p = 0.0345). No changes of GLR reductase activity were seen under all conditions indicated. Thus, the Lisinopril monotherapy and combined Lisinopril plus simvastatin therapy exhibit specific, pronounced and equipotent effects on antioxidant enzymes in human erythrocytes. Administration of Lisinopril or Lisinopril plus simvastatin may protect erythrocytes and other tissues from oxidative damage.
-
Erythrocyte antioxidant enzymes in hypertensive patients receiving Lisinopril monotherapy or combined Lisinopril plus simvastatin therapy
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2010Co-Authors: Elena Kosenko, A. V. Suslikov, N. I. Venediktova, Yu. G. KaminskyAbstract:Statins and angiotensin-converting enzyme (ACE) inhibitors have beneficial impact on the serum cholesterol and blood pressure. It is supposed that statins and ACE inhibitors may modify the antioxidative status in erythrocytes. The study objective was to compare the effects of two treatments, Lisinopril alone versus Lisinopril plus simvastatin, on erythrocyte antioxidant enzyme activities. The study involved 32 patients with arterial hypertension, their initial serum total cholesterol, LDL-cholesterol and triglycerides were within the normal range. Patients of two groups, each of 16 subjects, were treated with Lisinopril (10 mg/day) or with Lisinopril (10 mg/day) plus simvastatin (20 mg/day). Before and after the ambulatory therapy for 3 and 6 months, activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GR) were determined in purified erythrocytes. All treated patients had significantly higher catalase activity (by 79.3–106.5%, p < 0.0001) and significantly lower GPx activity (by 20.7–30.6%, p < 0.001) as compared to the baselines. The same results were obtained in both groups (Lisinopril and Lisinopril + simvastatin), after both periods (3 and 6 month) of treatments. SOD activity increased only in the Lisinopril group and only after 6 months (p = 0.0345). No changes of GR activity were observed under all conditions studied. Thus, the Lisinopril monotherapy and combined Lisinopril plus simvastatin therapy exhibit specific, pronounced and equipotent effects on antioxidant enzymes in human erythrocytes. Peroral administration of Lisinopril or Lisinopril plus simvastatin may protect erythrocytes and other tissues against oxidative damage.
-
Specific and pronounced impacts of Lisinopril and Lisinopril plus simvastatin on erythrocyte antioxidant enzymes.
Journal of clinical pharmacology, 2009Co-Authors: Yu. G. Kaminsky, Alexander Suslikov, Elena KosenkoAbstract:Angiotensin-converting enzyme inhibitors are effective at reducing blood pressure, whereas statins decrease plasma cholesterol impeding atherosclerosis. It is hypothesized that these medications may improve blood pressure and serum cholesterol by modifying the antioxidative status and energy metabolism of erythrocytes. In this study, the effects of 2 treatments are compared: Lisinopril alone versus Lisinopril + simvastatin, on erythrocyte antioxidant and energy metabolic enzymes. Patients with atherosclerosis and moderate hypertension are randomly assigned to receive Lisinopril 10 to 20 mg/d or Lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d for 24 weeks. Higher catalase activity and lower glutathione peroxidase activity are observed in 94% to 100% patients from both groups after 12 and 24 weeks of treatment. Superoxide dismutase activity is increased significantly only after 24 weeks. No changes of glutathione reductase, lactate dehydrogenase, and phosphofructokinase activities are found under any conditions indicated. Both treatments decrease systolic and diastolic blood pressure equally. Only Lisinopril + simvastatin treatment decreases plasma total cholesterol and low-density lipoprotein cholesterol. The results show for the first time that Lisinopril monotherapy and combined Lisinopril + simvastatin therapy exhibit specific and pronounced effects on antioxidant and energy metabolic enzyme activities in erythrocytes of hypertensive patients.
Elena Kosenko - One of the best experts on this subject based on the ideXlab platform.
-
Impacts of Lisinopril and Lisinopril plus simvastatin on erythrocyte and plasma arginase, nitrite, and nitrate in hypertensive patients.
Journal of clinical pharmacology, 2011Co-Authors: Elena Kosenko, Lyudmila A. Tikhonova, Alexander Suslikov, Yu. G. KaminskyAbstract:Angiotensin-converting enzyme inhibitors are effective at reducing blood pressure, whereas statins decrease plasma cholesterol, impeding atherosclerosis. The authors hypothesize that these medications may improve blood pressure by modifying the arginase-nitric oxide synthase system of erythrocytes. In this study, the effects of Lisinopril alone versus Lisinopril + simvastatin on erythrocyte and plasma arginase enzyme and nitric oxide metabolites are compared. Patients with atherosclerosis and hypertension are randomly assigned to receive Lisinopril 10 to 20 mg/d or Lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d for 24 weeks. Higher arginase activity is observed in erythrocytes from 100% of patients and mainly recovered after 12 and 24 weeks of treatment with Lisinopril or Lisinopril + simvastatin. Plasma arginase activity is 3 orders of magnitude lower than erythrocyte arginase activity in all participants, suggesting a lack of its clinical significance. Both treatments cause the increase in plasma $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ , $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ , and $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ + $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ in 100% of patients. Erythrocyte $$\hbox{ N }{\hbox{ O }}_{2}^{-}$$ + $$\hbox{ N }{\hbox{ O }}_{3}^{-}$$ concentration is greatly decreased in hypertensive patients but recovers after monotherapy and combined therapy. The results show for the first time that Lisinopril monotherapy and combined Lisinopril + simvastatin therapy exhibit pronounced and equipotential normalizing effects on erythrocyte arginase and nitric oxide synthase activities.
-
Antioxidant enzymes in erythrocytes from hypertension patients receiving Lisinopril monotherapy or combined Lisinopril plus simvastatin therapy
Biomeditsinskaia khimiia, 2011Co-Authors: Elena Kosenko, A. V. Suslikov, N. I. Venediktova, Yu. G. KaminskyAbstract:Statins and angiotensin-converting enzyme (ACE) inhibitors have beneficial impact on the serum cholesterol and blood pressure. It is supposed that statins and ACE inhibitors may modify the antioxidative status of erythrocytes. The study objective was to compare the effects of two treatments, Lisinopril alone vs Lisinopril plus simvastatin, on erythrocyte antioxidant enzyme activities. The study involved 32 patients with arterial hypertension, the initial serum total cholesterol, LDL-cholesterol and triglycerides within the normal range. Patients of two groups, each of 16 subjects, were treated with Lisinopril (10 mg/day) or with Lisinopril (10 mg/day) plus simvastatin (20 mg/day). Before and after 3 and 6 months of follow-up therapy, activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GLR) in purified erythrocytes were determined. In all patients, significantly higher catalase activity (by 79.3-106.5%, p < 0.0001) and significantly lower GPx activity (by 20.7-30.6%, p < 0.001) were observed after therapy as compared to the baselines. Just the same results were obtained in both groups (Lisinopril and Lisinopril + simvastatin), after both periods (3 and 6 month) of treatments. SOD activity was increased only in the Lisinopril group and only after 6 months (p = 0.0345). No changes of GLR reductase activity were seen under all conditions indicated. Thus, the Lisinopril monotherapy and combined Lisinopril plus simvastatin therapy exhibit specific, pronounced and equipotent effects on antioxidant enzymes in human erythrocytes. Administration of Lisinopril or Lisinopril plus simvastatin may protect erythrocytes and other tissues from oxidative damage.
-
Erythrocyte antioxidant enzymes in hypertensive patients receiving Lisinopril monotherapy or combined Lisinopril plus simvastatin therapy
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2010Co-Authors: Elena Kosenko, A. V. Suslikov, N. I. Venediktova, Yu. G. KaminskyAbstract:Statins and angiotensin-converting enzyme (ACE) inhibitors have beneficial impact on the serum cholesterol and blood pressure. It is supposed that statins and ACE inhibitors may modify the antioxidative status in erythrocytes. The study objective was to compare the effects of two treatments, Lisinopril alone versus Lisinopril plus simvastatin, on erythrocyte antioxidant enzyme activities. The study involved 32 patients with arterial hypertension, their initial serum total cholesterol, LDL-cholesterol and triglycerides were within the normal range. Patients of two groups, each of 16 subjects, were treated with Lisinopril (10 mg/day) or with Lisinopril (10 mg/day) plus simvastatin (20 mg/day). Before and after the ambulatory therapy for 3 and 6 months, activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GR) were determined in purified erythrocytes. All treated patients had significantly higher catalase activity (by 79.3–106.5%, p < 0.0001) and significantly lower GPx activity (by 20.7–30.6%, p < 0.001) as compared to the baselines. The same results were obtained in both groups (Lisinopril and Lisinopril + simvastatin), after both periods (3 and 6 month) of treatments. SOD activity increased only in the Lisinopril group and only after 6 months (p = 0.0345). No changes of GR activity were observed under all conditions studied. Thus, the Lisinopril monotherapy and combined Lisinopril plus simvastatin therapy exhibit specific, pronounced and equipotent effects on antioxidant enzymes in human erythrocytes. Peroral administration of Lisinopril or Lisinopril plus simvastatin may protect erythrocytes and other tissues against oxidative damage.
-
Specific and pronounced impacts of Lisinopril and Lisinopril plus simvastatin on erythrocyte antioxidant enzymes.
Journal of clinical pharmacology, 2009Co-Authors: Yu. G. Kaminsky, Alexander Suslikov, Elena KosenkoAbstract:Angiotensin-converting enzyme inhibitors are effective at reducing blood pressure, whereas statins decrease plasma cholesterol impeding atherosclerosis. It is hypothesized that these medications may improve blood pressure and serum cholesterol by modifying the antioxidative status and energy metabolism of erythrocytes. In this study, the effects of 2 treatments are compared: Lisinopril alone versus Lisinopril + simvastatin, on erythrocyte antioxidant and energy metabolic enzymes. Patients with atherosclerosis and moderate hypertension are randomly assigned to receive Lisinopril 10 to 20 mg/d or Lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d for 24 weeks. Higher catalase activity and lower glutathione peroxidase activity are observed in 94% to 100% patients from both groups after 12 and 24 weeks of treatment. Superoxide dismutase activity is increased significantly only after 24 weeks. No changes of glutathione reductase, lactate dehydrogenase, and phosphofructokinase activities are found under any conditions indicated. Both treatments decrease systolic and diastolic blood pressure equally. Only Lisinopril + simvastatin treatment decreases plasma total cholesterol and low-density lipoprotein cholesterol. The results show for the first time that Lisinopril monotherapy and combined Lisinopril + simvastatin therapy exhibit specific and pronounced effects on antioxidant and energy metabolic enzyme activities in erythrocytes of hypertensive patients.
Amir Azarpazhooh - One of the best experts on this subject based on the ideXlab platform.
-
an evidence based systematic review of the off label uses of Lisinopril
British Journal of Clinical Pharmacology, 2018Co-Authors: Seyyedreza Sadatebrahimi, Neda Parnianfard, Nafiseh Vahed, Hossein Babaei, Morteza Ghojazadeh, Sydney C W Tang, Amir AzarpazhoohAbstract:AIMS Lisinopril is an angiotensin-converting-enzyme inhibitor that is largely administered for off-label uses. This study aims to provide a comprehensive review of off-label uses of Lisinopril to aid physicians to make evidence-based decisions. METHODS The following bibliographic databases were searched from inception up to 30 March 2017: PubMed, EMBASE, the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, Ovid and Proquest. This systematic review sought all randomized trials conducted on adult individuals comparing Lisinopril on its off-label uses with alternative drugs or placebos and reported direct or alternative clinical outcomes. Risk of bias assessment by using the Cochrane Collaboration risk-of-bias tool and quality evaluation took place. RESULTS Included studies demonstrated significant positive effects of Lisinopril on proteinuric kidney disease; however, Lisinopril caused a slight reduction of glomerular filtration rate (GFR) especially for patients with GFR < 90 ml min–1. Lisinopril offered better outcomes in comparison to other standard treatments of diabetic nephropathy. Other studies showed positive effects of Lisinopril for migraine, prevention of diabetes, myocardial fibrosis, mitral valve regurgitation, cardiomyopathy in patients with Duchenne muscular dystrophy, oligospermia and infertility, and diabetic retinopathy. Conversely, the studies reported that Lisinopril was ineffective for five other off-label uses. CONCLUSIONS The identified studies showed that Lisinopril was highly effective for proteinuric kidney disease with a minor but inconsiderable decrease in GFR. Positive effects of Lisinopril were demonstrated in seven other off-label uses; however, Lisinopril cannot be recommended as the first choice for these until further clinical trials confirm these positive effects.
-
An evidence‐based systematic review of the off‐label uses of Lisinopril
British journal of clinical pharmacology, 2018Co-Authors: Seyyed-reza Sadat-ebrahimi, Neda Parnianfard, Nafiseh Vahed, Hossein Babaei, Morteza Ghojazadeh, Sydney C W Tang, Amir AzarpazhoohAbstract:AIMS Lisinopril is an angiotensin-converting-enzyme inhibitor that is largely administered for off-label uses. This study aims to provide a comprehensive review of off-label uses of Lisinopril to aid physicians to make evidence-based decisions. METHODS The following bibliographic databases were searched from inception up to 30 March 2017: PubMed, EMBASE, the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, Ovid and Proquest. This systematic review sought all randomized trials conducted on adult individuals comparing Lisinopril on its off-label uses with alternative drugs or placebos and reported direct or alternative clinical outcomes. Risk of bias assessment by using the Cochrane Collaboration risk-of-bias tool and quality evaluation took place. RESULTS Included studies demonstrated significant positive effects of Lisinopril on proteinuric kidney disease; however, Lisinopril caused a slight reduction of glomerular filtration rate (GFR) especially for patients with GFR
Hanshenrik Parving - One of the best experts on this subject based on the ideXlab platform.
-
long term effect of Lisinopril and atenolol on kidney function in hypertensive niddm subjects with diabetic nephropathy
Diabetes, 1997Co-Authors: F S Nielsen, Peter Rossing, Marianne Gall, P Skott, Ulla M Smidt, Hanshenrik ParvingAbstract:The aim of our study was to evaluate whether inhibition of ACE (Lisinopril 10-20 mg/day) can reduce the rate of decline in kidney function more than reducing blood pressure with conventional antihypertensive treatment (atenolol 50-100 mg/day), usually in combination with a diuretic. We performed a prospective, randomized, parallel study for 42 months, double blind for the first 12 months and single blind thereafter. Forty-three (21 Lisinopril and 22 atenolol) hypertensive NIDDM patients with diabetic nephropathy were enrolled. Data from 36 patients (17 Lisinopril and 19 atenolol, 60 +/- 7 years of age, 27 men) who completed at least 12 months of the study period are presented. At baseline, the two groups were comparable: glomerular filtration rate (51Cr-EDTA plasma clearance) was 75 +/- 6 and 74 +/- 8 ml x min(-1) x 1.73 m(-2), mean 24-h ambulatory blood pressure (A&D TM2420) was 110 +/- 3 and 114 +/- 2 mmHg, and 24-h urinary albumin excretion rate was 961 (range 331-5,727) and 1,578 (476-5,806) mg/24 h in the Lisinopril and atenolol groups, respectively. The mean follow-up time was similar, 37 and 35 months in the Lisinopril and atenolol groups, respectively. Mean ambulatory blood pressure was equally reduced in the two groups, 12 +/- 2 and 10 +/- 2 mmHg in the Lisinopril and atenolol groups, respectively. Glomerular filtration rate declined in a biphasic manner with a faster initial (0 to 6 months) change of 1.25 +/- 0.49 and 0.81 +/- 0.29 ml x min(-1) x month(-1) followed by a slower sustained decline (6 to 42 months) of 0.59 +/- 0.10 and 0.54 +/- 0.13 ml x min(-1) x month(-1) in the Lisinopril and atenolol groups, respectively. No significant differences were observed in either initial or sustained decline in glomerular filtration rate between the two groups. Urinary albumin excretion was reduced (% reduction of baseline) more in the Lisinopril than in the atenolol group, at 55 (95% CI 29-72) and 15% (-13 to 34), respectively (P = 0.01). In conclusion, the relentless decline in kidney function characteristically found in hypertensive NIDDM patients with diabetic nephropathy can be reduced equally effectively by two antihypertensive treatments, the beta-blocker atenolol and the ACE inhibitor Lisinopril.
-
differences between nisoldipine and Lisinopril on glomerular filtration rates and albuminuria in hypertensive iddm patients with diabetic nephropathy during the first year of treatment
Diabetes, 1997Co-Authors: Peter Rossing, Lise Tarnow, Soren Boelskifte, Berit R Jensen, F S Nielsen, Hanshenrik ParvingAbstract:Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (Lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy. We performed a 1-year, double-blind, doubledummy, randomized, controlled study comparing nisoldipine (20–40 mg once daily) with Lisinopril (10–20 mg once daily) in 52 hypertensive IDDM subjects with diabetic nephropathy. Three patients dropped out, and results for the remaining 49 (25 nisoldipine, 24 Lisinopril) are presented. Diuretics were required in 10 nisoldipineand 8 Lisinopril-treated patients. Every 3 months, 24-h ambulatory blood pressure (TM2420, AD GFR (51Cr-EDTA plasma clearance) was recorded every 6 months. Mean arterial blood pressure (24 h) was reduced from (mean ± SE) 108 ± 3 mmHg at baseline to 101 ± 2 in average during treatment in the Lisinopril group and from 105 ± 2 to 103 ± 2 in the nisoldipine group (P = 0.06 comparing changes in the two groups). Albuminuria was reduced 47% (95% CI 21–65) in the Lisinopril group versus an increase of 11% (−3 to 27) in the nisoldipine group ( P = 0.001). Fractional albumin clearance was reduced 37% (95% CI 4–59%) in the Lisinopril versus an increase of 35% (8–69%) in the nisoldipine group (P < 0.01). GFR decreased from 85 ± 5 ml · min−1 · 1.73 m−2 to 73 ± 5 in the Lisinopril group and from 84 ± 6 to 80 ± 7 in the nisoldipine group ( P < 0.05). The effect of study medication on albuminuria and GFR was independent of changes in systemic blood pressure and baseline variables in multiple regression analyses. In summary, Lisinopril reduced albuminuria, but also GFR, to a greater extent than did nisoldipine in hypertensive IDDM patients with diabetic nephropathy during the 1st year of treatment. Longer follow-up is required to clarify whether these drugs have different renoprotective effects.
-
impact of Lisinopril and atenolol on kidney function in hypertensive niddm subjects with diabetic nephropathy
Diabetes, 1994Co-Authors: F S Nielsen, Peter Rossing, Marianne Gall, P Skott, Ulla M Smidt, Hanshenrik ParvingAbstract:Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function. Angiotensin-converting enzyme inhibitors have been claimed to preserve kidney function better than an equal blood pressure (BP) reduction with conventional antihypertensive treatment (renoprotection). We compared the effect on kidney function of Lisinopril (10-20 mg/day) and atenolol (50-100 mg/day) in hypertensive NIDDM patients (mean age 60 +/- 8 years) with diabetic nephropathy. Forty-three (21 Lisinopril and 22 atenolol) patients were enrolled in a 1-year randomized double-blind parallel study. Eight patients dropped out, and the results for the remaining 35 patients (16 Lisinopril and 19 atenolol) are presented. Diuretics were required in 10 of 16 Lisinopril patients and 12 of 19 atenolol patients. The following variables were measured: 24-hour ambulatory BP (Takeda TM2420), albuminuria (enzyme-linked immunosorbent assay), fractional albumin clearance, and glomerular filtration rate (GFR) ([51Cr]EDTA technique). The average reduction in mean arterial BP during the 12 months was identical in the two groups 12 +/- 2 vs. 11 +/- 1 mmHg in the Lisinopril and atenolol group, respectively. Albuminuria was on average reduced 45% in the Lisinopril group vs. 12% in the atenolol group (P < 0.01), and fractional albumin clearance was on average reduced 49% in the Lisinopril group vs. 1% in the atenolol group (P < 0.05). GFR declined identically in the two groups 11.7 +/- 2.3 vs. 11.6 +/- 2.3 ml.min-1.year-1 in the Lisinopril and atenolol groups, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Munekazu Gemba - One of the best experts on this subject based on the ideXlab platform.
-
effects of efonidipine hydrochloride on renal arteriolar diameters in spontaneously hypertensive rats
Hypertension Research, 2002Co-Authors: Masuhisa Nakamura, Mitsuru Notoya, Yuka Kohda, Junji Yamashita, Yuko Takashita, Munekazu GembaAbstract:Efonidipine, a calcium antagonist, has been reported to dilate not only afferent but also efferent arterioles, thereby reducing glomerular hydrostatic pressure. We investigated the effect of chronic treatment with efonidipine or Lisinopril on the afferent and efferent arteriolar diameters by the vascular cast technique. Four-week-old spontaneously hypertensive rats (SHR) were divided into three groups: untreated, efonidipine (25 mg/kg/day)-treated, and Lisinopril (3 mg/kg/day)-treated. At 22 weeks of age, the renal vasculatures were fixed at the maximally dilated condition. The morphometrical measurements showed that the treatments with efonidipine and Lisinopril caused structural alteration of the vasculature, resulting in significantly greater efferent arteriolar diameters than in untreated SHR. In addition, Lisinopril-treated rats had wider afferent lumina. The renoprotective effect of efonidipine and Lisinopril might be partly due to the structurally larger efferent arteriolar lumen. (Hypertens Res 2002; 25: 751-755)